New RAS Inhibitor Doubles Survival in Pancreatic Cancer Plus Gut Microbiome Predicts Melanoma Recurrence
A phase III trial shows daraxonrasib doubled median survival in advanced pancreatic cancer, while gut bacteria may predict melanoma relapse risk.
Summary
A major oncology news roundup covers several findings relevant to longevity and disease prevention. Most notably, the RAS inhibitor daraxonrasib doubled median overall survival in advanced pancreatic cancer patients compared to chemotherapy in a phase III trial. Separately, gut microbiome composition may help predict whether melanoma returns after treatment, adding to growing evidence linking gut health to cancer outcomes. AI tools matched dermatologists in melanoma diagnosis accuracy, though experts warn AI reliance may erode physician skills over time. Updated breast cancer screening guidelines from the American College of Physicians recommend biennial mammograms for women 50–74, sparking debate. Higher e-cigarette taxes were linked to reduced vaping without increasing cigarette use, suggesting a harm-reduction benefit.
Detailed Summary
Pancreatic cancer has long carried one of the worst prognoses in oncology, making this week's phase III trial results particularly significant. Revolution Medicines reported that its investigational RAS inhibitor daraxonrasib nearly doubled median overall survival in previously treated advanced pancreatic cancer patients — 13.2 months versus 6.7 months on chemotherapy. RAS mutations drive a large proportion of pancreatic cancers, and this class of drugs has been a long-sought therapeutic target. While 13 months is still a limited survival window, this represents a meaningful step forward for a disease with few effective options.
On the melanoma front, researchers identified that specific gut microbiome signatures may predict the likelihood of melanoma recurring after treatment. This finding aligns with a growing body of evidence suggesting the gut microbiome plays a functional role in immune response and cancer surveillance — areas directly relevant to healthspan and disease prevention strategies.
AI continues to reshape oncology diagnostics. A study in JAMA Dermatology found AI systems matched dermatologists in melanoma diagnosis accuracy. However, a separate review cautioned that over-reliance on AI tools risks eroding the clinical expertise of physicians over time — a systemic concern for long-term healthcare quality.
Breast cancer screening guidelines were updated by the American College of Physicians, recommending biennial mammograms for average-risk women aged 50–74, while advising shared decision-making for women aged 40–49. The American College of Radiology strongly criticized these guidelines, warning they could lead to preventable deaths by delaying detection.
Finally, higher e-cigarette taxes correlated with reduced vaping frequency without driving users back to traditional cigarettes — a meaningful public health finding given vaping's links to lung disease and cancer risk. Taken together, this roundup reflects rapid movement across cancer prevention, early detection, and treatment — all central to extending healthy lifespan.
Key Findings
- Daraxonrasib doubled median overall survival vs chemotherapy in advanced pancreatic cancer (13.2 vs 6.7 months) in phase III trial.
- Specific gut microbiome bacteria may predict melanoma recurrence risk after treatment, linking gut health to cancer outcomes.
- AI matched dermatologist accuracy for melanoma diagnosis, but over-reliance may erode physician clinical skills over time.
- ACP recommends biennial mammograms for women 50–74; women 40–49 advised to discuss risks and benefits with their doctor.
- Higher e-cigarette taxes reduced vaping frequency without increasing conventional cigarette smoking.
Methodology
This is a curated news roundup from MedPage Today summarizing multiple recent oncology developments. Sources cited include a randomized phase III trial, peer-reviewed journals (JAMA Dermatology, Cancer Medicine, ESMO Real World Data), and institutional press releases. Evidence quality varies across items from phase III RCT data to preclinical models.
Study Limitations
This is a news summary, not a primary research article — key details such as trial size, patient demographics, and statistical confidence intervals are not provided. The biofield therapy finding is based only on preclinical models and should not be applied clinically. Readers should consult primary sources for full methodology and effect sizes before drawing conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.